Photoallergy Potential of Dapsone Gel in Healthy Volunteers
Information source: Allergan
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy Volunteers
Intervention: dapsone gel (Drug); dapsone gel vehicle (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Allergan Official(s) and/or principal investigator(s): Medical Director, Study Director, Affiliation: Allergan
Summary
This study will evaluate the potential of dapsone gel and its vehicle to cause a
photoallergic reaction after repeated application and irradiation to the skin of healthy
volunteers under controlled conditions.
Clinical Details
Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Photoallergic (Sensitizing) Potential Using a Visual Scale
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy adults.
Exclusion Criteria:
- Skin diseases, excessive hair, tattoos, pigmentation, scars or moles that could
interfere with patch application
- Sensitivity to adhesive bandages or tape.
Locations and Contacts
Fair Lawn, New Jersey, United States
Additional Information
Starting date: April 2014
Last updated: September 12, 2014
|